| 000 | 01858 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250516235533.0 | ||
| 264 | 0 | _c20150714 | |
| 008 | 201507s 0 0 eng d | ||
| 022 | _a1543-8392 | ||
| 024 | 7 |
_a10.1021/mp500460g _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHeskamp, Sandra | |
| 245 | 0 | 0 |
_aCetuximab reduces the accumulation of radiolabeled bevacizumab in cancer xenografts without decreasing VEGF expression. _h[electronic resource] |
| 260 |
_bMolecular pharmaceutics _cNov 2014 |
||
| 300 |
_a4249-57 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aCetuximab |
| 650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
| 650 | 0 | 4 |
_aErbB Receptors _xmetabolism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunoenzyme Techniques |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred BALB C |
| 650 | 0 | 4 | _aMice, Nude |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 | _aMultimodal Imaging |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xmetabolism |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aBoerman, Otto C | |
| 700 | 1 | _aMolkenboer-Kuenen, Janneke D M | |
| 700 | 1 | _aSweep, Fred C G J | |
| 700 | 1 | _aGeurts-Moespot, Anneke | |
| 700 | 1 | _aEngelhardt, Mallory S | |
| 700 | 1 | _avan der Graaf, Winette T A | |
| 700 | 1 | _aOyen, Wim J G | |
| 700 | 1 | _avan Laarhoven, Hanneke W M | |
| 773 | 0 |
_tMolecular pharmaceutics _gvol. 11 _gno. 11 _gp. 4249-57 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1021/mp500460g _zAvailable from publisher's website |
| 999 |
_c24258618 _d24258618 |
||